摘要
This editorial comments on the study by Ma et al,which delves into the efficacy and predictive factors associated with the combination of transarterial chemoembolization,lenvatinib,and programmed cell death protein-1 inhibition for the management of unresectable hepatocellular carcinoma.Analysing data from a retrospective study involving 102 patients,the treatment showcased a median overall survival(OS)of 26.43 months and a median progression-free survival(PFS)of 10.07 months.Notably,the objective response rate and disease control rate reached 61.76%and 81.37%,respectively.Specific factors such as Barcelona Clinic Liver Cancer(BCLC)Classification B-stage,early neutrophil-to-lymphocyte ratio re-sponse,and early alpha-fetoprotein response(>20%decrease)correlated with superior OS and PFS.The triple therapy exhibited promising efficacy,particularly in BCLC B-stage disease,with prognostic markers aiding in patient stratification.Acknowledging the retrospective nature of the study design,future research should address this limitation and incorporate longer follow-up periods for a comprehensive evaluation of long-term outcomes.
